Nucala 100 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FQQC8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $57,955
Award facts
- Contract value 100% obligated
- $57,954.90 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $57,954.90 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nucala 100 mg/mL syringes. The contract is a firm fixed-price delivery order with an ultimate completion date of January 22, 2026, and carries no set-aside designation, indicating the award was made through open competition. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish regional prime vendor contractors supplying pharmaceutical products to Department of Defense medical facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial performance as a critical supplier within the federal pharmaceutical supply chain, with its parent IDC—valued at $499.99 billion with a completion date of December 31, 2036—authorizing the company to deliver a comprehensive range of pharmaceuticals including branded and generic prescription drugs, biologics, vaccines, and medical consumables. The company's established track record of fulfilling diverse specialized pharmaceutical requirements for military healthcare operations globally positions it as a key vendor within the DLA's medical supply chain infrastructure. Nucala, an immunosuppressant biologic agent, represents one of the specialized pharmaceutical products the company regularly supplies to support Department of Defense healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FQQC8?
SPE2DR26FQQC8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 21, 2026.
How much is contract SPE2DR26FQQC8 worth?
The government has obligated $57,955 on SPE2DR26FQQC8.
Is contract SPE2DR26FQQC8 an order under another contract?
Yes. SPE2DR26FQQC8 is a delivery order under SPE2DR25D9331, an indefinite delivery contract.
Was contract SPE2DR26FQQC8 competed?
The extent of competition for SPE2DR26FQQC8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award